BOTANIX PHARMACEUTICALS LTD — Investor Presentation 2017

Apr 4, 2017

==> picture [166 x 74] intentionally omitted <==

ASX/Media Release

5 April 2017

Capital Raising Presentation

Philadelphia PA and Sydney Australia, 5 April 2017: Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or the “Company”) is pleased to provide the attached investor presentation. The presentation includes a summary of the Company, as well as an overview of the recently announced Placement, including structure, terms, proposed use of funds and indicative completion timetable.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy in 1H 2017 and plans to progress the development of its pipeline of other Permetrex[TM] enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit www.botanixpharma.com or follow us on Twitter @Botanixpharma.

For more information, please contact:

General enquiries

Matt Callahan Botanix Pharmaceuticals Ltd Executive Director P: +1 215 767 4184 E: mcallahan@botanixpharma.com

Investor Relations Ben Walsh WE Buchan P: (02) 9237 2801 E: bwalsh@buchanwe.com.au

Media enquiries

Arthur Chan WE Buchan P: (02) 9237 2805 E: achan@buchanwe.com.au

==> picture [138 x 154] intentionally omitted <==

==> picture [215 x 318] intentionally omitted <==

Capital Raising Presentation April 2017

==> picture [139 x 540] intentionally omitted <==

+ Capital raising summary

+

==> picture [79 x 27] intentionally omitted <==

Capital raising overview

Received commitments to raise up to A$7.4m via an oversubscribed Placement; will introduce a number of leading institutional and sophisticated investors to the register

• Capital raising via a Placement to institutional and sophisticated investors to raise up to A$7.4m

• New shares will be issued at an offer price of A$0.055 per share

Overview

• Offer price represents a 13.3% discount to the 20-day volume weighted average price (as at 30 March 2017)

• Placement was substantially oversubscribed, as well as strongly supported by existing and new institutional and sophisticated investors

• Tranche 1 is an unconditional c. A$5.4m Placement of 97.9m shares issued under the Company’s existing placement capacity pursuant to ASX Listing Rules 7.1 and 7.1A

Structure

• Tranche 2 is a conditional c. A$2.0m Placement of 36.4m shares, subject to shareholder approval at the EGM

• Placement shares to be fully paid and rank equally with existing Botanix shares

Ranking and timing

• Allotment of Placement shares under Tranche 1 to occur on Wednesday, 12 April 2017

• Indicative date of EGM is Monday, 15 May 2017 (a Notice of Meeting will be dispatched shortly)

Botanix Pharmaceuticals Ltd.

3

+

==> picture [79 x 27] intentionally omitted <==

Use of funds

Compelling use of funds to accelerate the clinical programs of pipeline products and Permetrex[TM] commercial opportunities

Overview

• Dual development of BTX 1503 (acne) and BTX 1204 (dermatitis) improves the probability of clinical success and enhances Botanix’s value

• Development of BTX 1701 (acne cleanser/wash), that does not require FDA approval, allows Botanix to potentially generate near term revenue

• Flexibility to explore the commercial potential of Permetrex[TM] , with the ability to potentially generate near term revenue through licensing and partnership agreements

Proposed use of funds[1]

Proposed use of funds1
	A$m
BTX 1503 FDA Phase II IND submission data generation and preparation	0.4
BTX 1204 preparation/manufacturing for dermatitis pilot study	1.1
BTX 1204 dermatitis pilot study	1.5
BTX 1701 manufacturing and pilot study	0.4
BTX 1701 clinical study	1.8
PermetrexTM pipeline technology support and development	1.5
Cost of offer	0.6
Total use of funds	7.4

Notes:

Botanix Pharmaceuticals Ltd.

4

1. Individual use of funds figures may not add to A$7.4m due to rounding

+

==> picture [79 x 27] intentionally omitted <==

Capital raising timetable

Botanix is working to the indicative timetable laid out below

Indicative capital raising timetable[1]

Trading halt	Friday, 31 March 2017
Closing date for receipt of firm and irrevocable bids	(4pm AWST) Monday, 3 April 2017
Allocations and offer confirmation letters sent to Placement participants	Monday, 3 April 2017
Confirmation of allocation to Lead Manager by Placement participants	Tuesday, 4 April 2017
Placement announced and Company resumes trading	Wednesday, 5 April 2017
Settlement of Placement shares via DvP under Tranche 1	Tuesday, 11 April 2017
Allotment of Placement shares under Tranche 1	Wednesday, 12 April 2017
EGM for approval of issue of Placement shares under Tranche 2	Monday, 15 May 2017
Settlement of Placement shares under Tranche 2	Thursday, 18 May 2017
Allotment of Placement shares under Tranche 2	Friday, 19 May 2017

Notes:

1. The timetable above is indicative only and may be varied subject to the ASX Listing Rules

Botanix Pharmaceuticals Ltd.

5

==> picture [139 x 540] intentionally omitted <==

+ Overview of Botanix Pharmaceuticals

+

==> picture [79 x 27] intentionally omitted <==

Investment highlights

Botanix is one of the most compelling emerging companies on the ASX

• Experienced US based leadership team with FDA approvals track record

• Growing, multi-billion dollar dermatology markets with no new products approved in last 20 years (for acne)

• Key products based on pharmaceutical grade synthetic cannabidiol (versus variable naturally derived cannabidiol), greatly enhances the probability of clinical and regulatory success

• Exclusive global rights to use Permetrex[TM] delivery technology for all skin diseases with potential to deliver near term revenues

• Accelerated development pathway for dermatology products compared to standard development pathways, driving lower development costs and a faster timeline to approval

• Strong intellectual property portfolio including 12 patent applications across 6 patent families, along with specific dermatology know-how and trade secrets

• Multiple near term potential revenue streams to complement medium term development upside

Botanix Pharmaceuticals Ltd.

7

+

==> picture [79 x 27] intentionally omitted <==

Corporate overview

Innovative medical dermatology company with a clear path to commercialisation, and a highly aligned Board and management team holding 39% of Botanix shares

Trading information

Share price performance

Share price (30-Mar-17)	A$0.068
52 week low / high	A$0.026 / A$0.075
Shares on issue1,2	408.8m
Market capitalisation	A$27.8m
Cash (as at 31-Dec-16)2	A$2.4m
Debt (as at 31-Dec-16)	Nil
Enterprise value	A$25.4m

==> picture [350 x 296] intentionally omitted <==

----- Start of picture text -----

Share price (A$) Volume (m)
0.08 100
0.06 75
0.04 50
0.02 25
- -
Jul-16 Sep-16 Nov-16 Jan-17 Mar-17
Volume (RHS) BOT S&P/ASX 300 Health Care Index
----- End of picture text -----

Top shareholders (as at Apr 2017, pre-placement)

Shareholder %	Shareholder %
Matthew Callahan –Executive Director	17.3
Caperi Pty Ltd –Co-founder	17.3
Board and management (excl. shareholders above)	5.0

Source: IRESS

Botanix Pharmaceuticals Ltd.

8

1. Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018 2. Excludes 38.8m unlisted options with exercise price range of A$0.03 - A$0.133 and expiry date range of Dec 2016 to Jun 2019

+

==> picture [79 x 27] intentionally omitted <==

Recent corporate and product development

Recent corporate developments have provided a strong platform for Botanix to accelerate its clinical development program

Corporate milestones

Apr/May 2017

Jul 2016

Jul 2016 to Feb 2017

Feb 2017

Mar 2016

A$7.4m placement to institutional and sophisticated investors

Key staff hires across the business divisions of clinical and regulatory, manufacturing, toxicology and operations

Completed RTO and commencement of trading as Botanix Pharmaceuticals (ASX:BOT)

Completed expansion of Permetrex™ license to cover the delivery of all drug actives used in treating skin diseases

Pre-RTO: Bone Medical announce reverse take over (RTO) by Botanix Pharmaceuticals

==> picture [527 x 56] intentionally omitted <==

Development milestones

Jul 2016

Nov 2016

Dec 2016

Mar 2016

Manufactured BTX 1503 trial formulation using FDA quality components

Completed first human safety and irritation study with Permetrex[TM]

Ethics approval received for first human study utilising BTX 1503

Secured access to commercial scale synthetic cannabidiol

Funding in place to accelerate advancement of clinical products, and potential licensing and partnership arrangements for Permetrex[TM]

Commencement of clinical trials of BTX 1503 and BTX 1204, and development of BTX 1701 cleanser/wash

Formulation

Confirm Permetrex[TM] Safety

Proof of Concept

Key milestones achieved

Near term focus

Botanix Pharmaceuticals Ltd.

9

+

==> picture [79 x 27] intentionally omitted <==

Senior leadership: track record of success

Proven industry professionals with a demonstrated ability to lead the development, financing, regulatory approval and commercialisation of pharmaceuticals

==> picture [43 x 56] intentionally omitted <==

==> picture [43 x 55] intentionally omitted <==

==> picture [43 x 56] intentionally omitted <==

==> picture [43 x 56] intentionally omitted <==

Expertise: corporate + IP

Mr Matthew Callahan

Executive Director (Appointed Jul 2016)

• Founding CEO of iCeutica Inc, which has developed 3 products to date that have received FDA approval

• Previous investment director of 2 venture capital firms investing in life sciences

Expertise: manufacturing + IP

Dr Bill Bosch

Executive Director (Appointed Jul 2016)

• 6 FDA approved products to date and co-inventor of the iCeutica SoluMatrix Technology

• Managed the commercial development of 4 nanotechnology products at Elan Corporation

• Co-founder of NanoSystems and the co-inventor of the drug delivery technology NanoCrystal

Expertise: ops + regulatory

Dr Michael Thurn

Chief Operating Officer (Appointed Feb 2017)

• Extensive start up life sciences experience across a range of technology platforms

• Previous Managing Director of Spinifex Pharmaceutical, which was taken out by Novartis for A$700m

Expertise: regulatory + clinical

Dr Mark Davis

VP Clinical and regulatory (Appointed Aug 2017)

• 30 years of clinical experience with 19 FDA approved products across dermatology and injectables

• Unique experience with synthetic cannabidiol at Insys Therapeutics

• Former clinical lead with Medicis and Connetics

20+ FDA approved products credited to the broader Botanix leadership team

==> picture [175 x 288] intentionally omitted <==

Botanix Pharmaceuticals Ltd.

10

+

==> picture [79 x 27] intentionally omitted <==

Strategic and commercialisation focus

Primary strategy is commercialising BTX 1503, with supportive pipeline of other medical dermatology products

==> picture [636 x 141] intentionally omitted <==

----- Start of picture text -----

Active pharmaceutical
Cannabidiol
Botanix product BTX 1503 Permetrex [TM] BTX 1308 BTX 1204
Delivery technology
Clinical application Acne Psoriasis Dermatitis
----- End of picture text -----

Near term focus

Near to medium term focus

Medium to long term focus

BTX 1503 development and commercialisation

Permetrex[TM] licensing

==> picture [207 x 43] intentionally omitted <==

----- Start of picture text -----

Other pipeline products
----- End of picture text -----

• Accelerating clinical development through undertaking low cost first clinical studies in Australia, feeding into a US based FDA approval

• Licensing Permetrex[TM] delivery system to strategic parties, to generate potential near term revenue

• Leverage data from BTX 1503 program to accelerate development of new products in psoriasis and dermatitis

• Utilising Permetrex[TM] to develop other pipeline products for near term outlicensing

Botanix Pharmaceuticals Ltd.

11

+

==> picture [79 x 27] intentionally omitted <==

Significant and growing market opportunity

Global acne prescription products market expected to grow to >US$4.5bn by 2018, driven by the significant US market and is only a subset of the global dermatology opportunity

Value of the global acne prescription market is expected to reach US$4.5bn by 2018[1]

Top branded acne products containing only generic drugs have achieved revenues of up to >US$300m p.a.[2]

==> picture [664 x 141] intentionally omitted <==

----- Start of picture text -----

US$331m
US$4,530m 2011
US$285m
2012
US$199m 2013
US$175m US$168m US$167m
US$3,951m
US$3,845m US$95m
US$85m
2012 2013 2018 Epiduo Aczone Tazorac Differin Acanya Ziana Benzaclin Atralin
(Galderma) (Allergen) (Allergen) (Galderma) (Valeant) (Valeant) (Valeant) (Valeant)
(Valeant)
----- End of picture text -----

Large demand with limited recent product development

• 50 million patients (in the US alone) used an acne product in 2015

• No new chemical entities have been approved by the FDA in the last 20 years for the treatment of acne

• Only “new” products launched in this period were combinations of old drugs in new formulations or new packaging

• Little development expected in future years, with very few products currently in the development pipeline

• Acne is just a subset of an even larger dermatology market opportunity (psoriasis, eczema, etc.) which is in the order of US$20bn p.a.

• BCC Research, May 2013. Skin Disease Treatment and Global Markets

Botanix Pharmaceuticals Ltd.

12

1. Symphony Health Solutions, Pharmaceutical Audit Suite for 2012 as reported in Demira S1

+

==> picture [79 x 27] intentionally omitted <==

Botanix’s most advanced product – BTX 1503

BTX 1503 is topically applied for the treatment of moderate and severe acne utilising a novel skin delivery technology called Permetrex[TM]

Overview

Cannabidiol mechanism of action in acne

• BTX 1503 is a formulation of pure, synthetic cannabidiol that is administered via the Permetrex[TM ] delivery system

• Cannabidiol is a chemical that can be naturally extracted in raw form from the cannabis plant

• Cannabidiol has an established safety profile with >100 human clinical trials completed or underway, in a range of different diseases

• Cannabidiol has anecdotally been found to be effective in treating a range of skin diseases

• BTX 1503 is designed to maximise the delivery of cannabidiol to the sebaceous glands with little systemic exposure

Lipostatic	Normalises excessive and abnormal fatty oil production known as “sebum”
Anti-inflammatory	Induces a novel anti-inflammatory pathway
Anti-proliferation	Inhibits proliferation of sebum producing sebocytes (cells), without affecting their viability (an important safety aspect)
Anti- bacterial	Demonstrated anti-bacterial targeting acne specific_Propionibacterium acnes (P. acnes)_

Source: Cannabidiol exerts sebostatic and anti inflammatory effects on human sebocytes (2014).The Journal of Clinical Investigation

Botanix Pharmaceuticals Ltd.

13

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 market positioning

BTX 1503 has the potential to be the market leading product for acne treatment with no undesirable side effects

Market landscape for acne treatments[1]

• BTX 1503 has multiple mechanisms of action that directly treat the key pathogenic factors causing acne, making it a potentially superior treatment to existing therapies

• While systematic therapies (i.e. oral isotretinoin) may inhibit sebum (skin-oil) production, its use is limited by very serious side-effects

• Significant market opportunity; major existing treatments fetched annual revenues in the range of US$700m-US$800m when they were patented products

• BTX 1503’s patent protection is a significant competitive advantage, as all other treatments below are now generic products

Method of action	BTX 1503	Clindamycin	Tretinoin	Adapalene	Minocycline	Erythromycin	Accutane
Reduces excessive sebum (skin oil) production	✓						✓
Anti-inflammatory	✓		✓	✓			✓
Anti-bacterial	✓	✓			✓	✓	✓
Topical (applied to a specific area of the body)	✓		✓	✓
Minimal side effects	✓		✓	✓		✓
Patent protected (not a generic product)	✓

1. Subject to relevant successful development and approvals

Botanix Pharmaceuticals Ltd.

14

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 key advantages

Synthetic cannabidiol and a proprietary skin delivery system provides significant competitive advantages compared to other products in development

Challenge 1

Significant commercial and regulatory hurdles in extracting sufficient naturally derived cannabidiol at the required purity, lowers the chance of achieving clinical success

Challenge 2

Medicinal cannabidiol is generally administered orally, however, only 6% of cannabidiol consumed orally is available in the blood stream (even less makes it to the target organs in the skin)

Botanix solution

Botanix solution

Synthetically derived cannabidiol allows for consistent manufacturing, greater scalability and more straightforward regulatory approval prospects

Permetrex[TM ] delivers cannabidiol efficiently into the skin for the targeted treatment of various skin diseases.

Advantages of synthetic cannabidiol

Synthetic cannabidiol Naturally extracted cannabidiol 1 chemical 100+ chemicals 100% pure Multiple impurities Scaled up to ~50kg Scaled up to ~1kg Material registered with FDA Not registered with FDA No additional Must comply with FDA’s compliance required “Botanical Drug Development Guidance for Industry”

==> picture [278 x 144] intentionally omitted <==

----- Start of picture text -----

Unmodified drug With Permetrex [TM]
Epidermis
Dermis
----- End of picture text -----

Botanix holds the exclusive rights to utilise Permetrex[TM] for all drugs that treat skin diseases

Botanix Pharmaceuticals Ltd.

15

+

==> picture [79 x 27] intentionally omitted <==

BTX 1503 accelerated clinical development

Botanix is pursuing a rapid clinical development strategy in order to minimise the time until product commercialisation and first revenues

• In December 2016, Botanix completed its first human study of the Permetrex[TM] delivery technology and successfully showed that Permetrex[TM] did not cause any safety or irritation issues

• First enrolment of Phase Ia acne study estimated for 2Q CY2017, with study data also planned to be available by the end of 2Q CY2017

• Botanix is fully funded for the Phase Ia and Phase Ib clinical trials of BTX 1503

BTX 1503 indicative clinical timeline	Q1 2017		Q2 2017		Q3 2017		Q4 2017		Q1 2018		Q2 2018		Q3 2018		Q4 2018
Ethics approval for Phase I BTX 1503 trial
Phase Ia safety, dosing and pharmacokinetic trial
Phase Ib acne pilot study
Manufacturing and FDA approval for Phase II trial
Phase II clinical trial

==> picture [20 x 23] intentionally omitted <==

Clinical milestones where potential development partnerships and/or licensing agreements may be considered

Botanix Pharmaceuticals Ltd.

16

+

==> picture [79 x 27] intentionally omitted <==

Accelerated development timeline

Botanix is executing on an efficient, more economical and less risky clinical development strategy compared to traditional pharmaceutical development pathways Botanix’s accelerated indicative clinical timeline

Proven ability to execute: Achieved since listing

Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing	Proven ability to execute:Achieved since listing
Phases			Botanix approach Costs (est.) Timing (est.) ~$1m ~6 months
	Traditional process
	Costs (est.)	Timing (est.)	Costs (est.)
Discovery and pre-clinical	~$430m	~5 years	~$1m
Investigational New Drug or equivalent	~$1m
Phase I clinical	~$25m	~7 years
			~$2m	~6 months ~28 months ~12 months ~4 years
Phase II clinical	~$35m		~$5m
Phase III clinical	~$54m		~$20m
New Drug Application	~$5m	~2 years	~$2m
Total	~$460m	~14 years	~$30m

• Botanix is pursuing an accelerated development timeline, due to:

• Minimal pre-clinical development due to known safety profile of cannabidiol

• Dermatology studies tend to be shorter in duration and require smaller study populations

• Objective measurements of efficacy (end points are typically visual assessments)

• Opportunity to generate near term revenue from potential licensing agreements for Permetrex[TM]

• Known safety profile increases probability of successful clinical development

Botanix Pharmaceuticals Ltd.

17

+

==> picture [79 x 27] intentionally omitted <==

Commercialisation strategy

Botanix’s focused and accelerated timeline to product commercialisation results in significant potential value uplift

Efficient commercialisation path with multiple options

Value uplift

• Continued clinical development success is reflected in significant value uplift after each successive phase

• Typically monetised via licensing, partnering and/or sale/merger opportunities

• Additional indications can be partnered while pursuing acne focus

• Potential future revenue streams:

• Product licensing agreements

• Partnership with strategic parties

• Product sales revenue

==> picture [371 x 269] intentionally omitted <==

----- Start of picture text -----

Significant value uplift potential at the
completion of each phase of development
(as evidenced by recent dermatology
Phase 3
transactions)
(~ 24 months)
Phase 2
(~ 12 months)
Phase 1 Investment decision
(< 12 months)
License, partner and/or
sale opportunities
----- End of picture text -----

==> picture [30 x 11] intentionally omitted <==

----- Start of picture text -----

Time
----- End of picture text -----

Botanix Pharmaceuticals Ltd.

18

+

==> picture [79 x 27] intentionally omitted <==

Recent dermatology transactions

Licensing and partnering transactions are potential monetisation options

Dermatology transactions

==> picture [664 x 334] intentionally omitted <==

----- Start of picture text -----

US$5,200m
Licensing deals
US$790m Total upfront and US$770m
milestone payments US$639m
could exceed these
US$445m figures in aggregate
US$150m
US$90m
Deal date Sep 15 Dec 2016 Jan 2016 Dec 2016 Oct 2016 Apr 2016 May 2016
Deal type License License Corporate Corporate Corporate Asset/business Corporate
Licensee/Acquirer Allergan
Licensor/Target
(global dermatology
(rights) business)
In pre-clinical
In pre-clinical
Phase In Phase III Completed Phase I development / In Phase II On market Completing Phase III
development
Phase IIb
----- End of picture text -----

Source: Bloomberg, Company disclosure

Botanix Pharmaceuticals Ltd.

19

+

==> picture [79 x 27] intentionally omitted <==

Clinical development pipeline

Development pipeline also includes other synthetic cannabidiol clinical products targeting key dermatology markets

These products will leverage both the BTX 1503 synthetic cannabidiol clinical program as well as the Permetrex[TM] delivery system

BTX 1204: dermatitis

BTX 1308: psoriasis

• Target market: 7.5 million Americans have psoriasis (most have plaque psoriasis)

• Target market: US patient incidence estimated to be 31 million (10% to 18% of children)

==> picture [128 x 135] intentionally omitted <==

Psoriasis

• Market size: estimated annual cost of treating atopic dermatitis in the US is ~US$4bn

• Current issues: most treatments on the market (i.e. steroids) only address the symptoms

Funded through to the completion of human clinical study

• Market size: estimated annual costs of injectable biologic treatments in the US is ~US$20bn

• Current issues: biologic drugs are very expensive have serious side effect issues (including lymphoma)

==> picture [128 x 119] intentionally omitted <==

Dermatitis

Botanix Pharmaceuticals Ltd.

20

+

==> picture [79 x 27] intentionally omitted <==

OTC development pipeline

Development pipeline includes “over the counter” products with near term potential, that can be developed and marketed without FDA approval

Top 10 facial cleaners based on sales

BTX 1701: cleanser/wash

• Target market: 50 million patients in the US alone purchased an acne treatment product in 2015

• Market size: ~US$1bn+ p.a. for cleansers and washes

• Comments: acne treatment products (e.g. cleansers) will utilise the novel Permetrex[TM] delivery system

This product can be developed and marketed without FDA approval

		Change in	Unit sales	Change in
	Sales (US$m)	sales (%)	(m)	unit sales (%)
Private label	137.5	6.0	33.5	5.2
Bioré	68.3	47.5	9.4	53.1
Simple	54.3	5.8	9.5	2.3
Cetaphil	51.1	22.2	5.8	12.0
Olay	46.6	-9.6	7.6	-10.1
Burt’s Bees	46.0	21.3	7.1	23.1
Johnson’s Clean & Clear Morning Burst	40.0	-4.1	11.0	3.4
CeraVe	39.8	24.1	3.7	33.4
Neutrogena Deep Clean	37.0	-4.9	5.9	-5.1
Pond’s	33.4	4.5	7.0	0.5

==> picture [98 x 101] intentionally omitted <==

Source: IRI for the 52 weeks ended May 15 across total U.S. multi-outlet (supermarkets, drug stores, mass market retailers, military commissaries and select club and dollar retail chians)

Botanix Pharmaceuticals Ltd.

21

+

==> picture [79 x 27] intentionally omitted <==

Valuable intellectual property portfolio

Botanix has protected its suit of development products through various patent applications across key global markets

• Botanix currently has 12 patent applications across 6 different patent families

• Patents applications cover lead acne product and other Permetrex[TM] enabled products

• Patent protection targeted at key geographic regions with large and viable dermatology markets (i.e. initially US and Australia, but following into the EU, UK, Japan, India, China, South America and other jurisdictions in National phase)

• Botanix positioned as the leading player in the sector – underpinned by substantial volumes of proprietary knowledge, manufacturing know-how and trade secrets

• Additional IP opportunities will be pursued on each Permetrex[TM] product developed internally or with partners

==> picture [377 x 297] intentionally omitted <==

----- Start of picture text -----

Expanded patent applications for
BTX 1503 and other Permetrex [TM]
enabled products
Initial patent applications protecting
BTX 1503
----- End of picture text -----

Botanix Pharmaceuticals Ltd.

22

+

==> picture [79 x 27] intentionally omitted <==

Botanix vs. ASX-listed medical cannabis companies

Botanix is the most compelling early stage cannabis related opportunity on the ASX

Botanix’s competitive advantages :

• Synthetic cannabidiol formulation -  probability and speed of FDA approval

• Unmet clinical need - No FDA approved acne treatments in last 20 years

• Significant addressable market - $4.5 billion in annual prescription sales of acne products

• Faster development pathway – simple end points and skin based administration

==> picture [660 x 265] intentionally omitted <==

----- Start of picture text -----

186
155
141
Potential for re-rating given competitive advantages
84
61
Market 49
capitalisation 28
(A$m) [1]
Botanix Creso Pharma Zelda Therapeutics MGC MMJ PhytoTech Medlab Clinical AusCann Group
Pharmaceutical (ASX:CPH) (ASX:ZLD) Pharmaceuticals (ASX:MMJ) (ASX:MDC) (ASX:AC8)
(ASX:BOT) (ASX:MXC)
Focus Dermatology Nutraceutical Oncology/ Dermatology/ Epilepsy Oncology Epilepsy/
Dermatology Epilepsy Oncology
Drug Source Synthetic Natural Natural Natural Natural Natural Natural
Administration Topical Oral Variable Variable Variable Mouth spray Oral
----- End of picture text -----

Source: IRESS, Company disclosure

Botanix Pharmaceuticals Ltd.

23

1. Market capitalisation as at close 4 April 2017 and calculated via the following formula (ordinary shares on issue + ordinary shares subject to escrow)*share price

+

==> picture [79 x 27] intentionally omitted <==

ASX market landscape

An accelerated clinical development timeline and near term catalysts should support a sustained re-rating in market valuation

Botanix vs. early stage ASX-listed pharmaceutical and biotechnology companies

Botanix’s clinical development pathway is de-risked compared to peers :

• Simple clinical trials with an accelerated development timeline - ↓ time and cost to achieve FDA approval

• Targeting an unmet clinical need with large market opportunity and few competing products in development

• Permetrex[TM] is a highly flexible technology with a broad opportunity base and near term revenue potential

==> picture [660 x 257] intentionally omitted <==

----- Start of picture text -----

175 176
Potential for re-rating given clinical
development is de-risked compared to peers
Market
49
capitalisation 28 30
(A$m) [1]
Botanix Pharmaceuticals Orthocell (ASX:OCC) Paradigm Innate Bionomics (ASX:BNO)
(ASX:BOT) Biopharmaceuticals Immunotherapeutics
(ASX:PAR) (ASX:IIL)
Hay fever / Bone Oncology/ Central
Focus Dermatology Regenerative Multiple Sclerosis
Marrow Edema Nervous System disease
Accelerated Development ✓ ✓ ✓
Near term revenue ✓ ✓ ✓
----- End of picture text -----

Source: IRESS, Company disclosure

Botanix Pharmaceuticals Ltd.

24

1. Market capitalisation as at close 4 April 2017 and calculated via the following formula (ordinary shares on issue + ordinary shares subject to escrow)*share price

+

==> picture [79 x 27] intentionally omitted <==

International landscape

Botanix represents a significant value accretive opportunity when compared to key global peers with positive Phase I and Phase II data

Market capitalisation of key international peers[1]

Zynerba share price performance (US$)

==> picture [330 x 308] intentionally omitted <==

----- Start of picture text -----

US$1,383m
US$343m
US$269m
US$100m
Novan Zynerba Cassiopea Dermira
Dermatology ✓ ✓ ✓
focused
Cannabidiol ✓
focused
No. of
Multiple Multiple Multiple Multiple
products
Glycopyrronium
SB206: II Winlevi©:III
Clinical ZYN002 CBD Gel: II Tosylate:III
SB208: II Breezula©:III
development SB414: I ZYN001 THC Pro- CB-06-01: II CIMZIA©:III
phase SB414: I Drug Patch: I CB-06-02: II Olumacostat
Glasaretil:III
----- End of picture text -----

==> picture [309 x 124] intentionally omitted <==

----- Start of picture text -----

24
Announced positive
20 ZYN002 Phase I
results
16
12
8
Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17
----- End of picture text -----

Dermira share price performance (US$)

==> picture [309 x 123] intentionally omitted <==

----- Start of picture text -----

28
Announced positive
24
DRM01 Phase II
results
20
16
12
Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15
----- End of picture text -----

Source: Bloomberg, Company disclosure

Botanix Pharmaceuticals Ltd.

25

1. Market capitalisation figures as at close 30 March 2017

+

==> picture [79 x 27] intentionally omitted <==

Key catalysts

Significant operational milestones expected over the next 9 months, as Botanix launches first human studies and accelerates corporate development

2Q CY2017

3Q/4Q CY2017

	2Q CY2017		3Q/4Q CY2017
	▪Study commencement of BTX 1503 Phase Ia		▪Commencement (and completion) of BTX
	safety study		1503 Phase Ib acne pilot study and results
Indicative BTX 1503	▪Study data from BTX 1503 Phase Ia safety		▪Collaboration on cannabidiol program with
milestones	study		external partner
	▪Submission of ethics approval for BTX 1503		▪Preparation for Phase II BTX 1503 clinical
	Phase Ib acne pilot study		study and FDA submissions
	▪Commencement of BTX 1204 formulation		▪Commencement of BTX 1204 pre-clinical
Other indicative	manufacturing and testing work		testing (dermatitis)
product	▪Commencement of BTX 1701 manufacturing		▪Commencement and completion of BTX 1701
development and	and testing work		clinical study
PermetrexTM	▪Study commencement and data from BTX		▪New product additions to pipeline (utilising
commercialisation	1701 pilot study		the Permetrex™ technology)
milestones	▪Sign collaboration agreement for PermetrexTM		▪Sign collaboration agreement on pipeline
	technology with external strategic partner		product/s

Botanix Pharmaceuticals Ltd.

26

==> picture [139 x 540] intentionally omitted <==

Appendix + Board of Directors, corporate history, commercialisation strategy, clinical development, and clinical team

+

==> picture [79 x 27] intentionally omitted <==

Botanix Board of Directors

Highly credentialed Board of Directors with a proven record of building and leading successful pharmaceuticals businesses

==> picture [720 x 59] intentionally omitted <==

Graham Griffiths Chairman Appointed July 2016

Matthew Callahan Executive Director Appointed July 2016

Dr Bill Bosch Executive Director Appointed July 2016

Rob Towner Director Appointed July 2016

• 40 years executive experience in technology based companies, across sales, marketing and product development

• Former Managing Director of ipernica, responsible for acquisition and commercialisation of nearmap.com (ASX:NEA)

• Non-Executive Director of Pointerra (ASX:3DP), iperative and NGIS Australia

==> picture [25 x 16] intentionally omitted <==

Commercialisation

• Founding CEO of iCeutica and Churchill Pharmaceuticals

• Co-inventor of iCeutica’s SoluMatrix Technology

• Developed 3 FDA approved products

• Investment director at 2 venture capital firms

• 20 years experience in legal, IP and investment management

• Director of Orthocell (ASX:OCC) and Glycan Bioscience LLC

==> picture [26 x 16] intentionally omitted <==

Corporate and IP

• 20 years corporate advisory experience

• 20 years experience in the pharmaceutical industry

• Founder and sole director of Cornerstone Corporate

• Co-inventor of iCeutica’s SoluMatrix Technology

• Developed 6 FDA approved ▪ Founding Executive Director of products bioMD

• Developed 4 commercial ▪ bioMD merged with Allied nanotechnology products at Elan Health Care in 2011 to form Corporation Admedus (ASX:AHZ, $200m market capitalisation)

• Co-founder of NanoSystems LLC and co-inventor of NanoCrystal Technology

• Executive Director of Triangle Energy (ASX:TEG)

==> picture [26 x 15] intentionally omitted <==

==> picture [25 x 16] intentionally omitted <==

Manufacturing and IP

Financing and capital markets

Botanix Pharmaceuticals Ltd.

28

+

==> picture [79 x 27] intentionally omitted <==

Botanix executive management

Highly credentialed clinical development team with extensive expertise in leading novel products through clinical and regulatory development

Dr Mark Davis VP Clinical and Regulatory

• 30 years of clinical experience with 19 FDA approved products

• Unique experience with cannabidiol through Insys

• Former clinical lead with Medicis and Connetics

Clinical and regulatory

Dr Michael Thurn Chief Operating Officer

• Extensive start up life sciences experience across a range of technology platforms

• +20 years experience in drug regulation, drug discovery, pre-clinical and clinical

• Previous Managing Director of Spinifex Pharmaceuticals

Regulatory and operations

Dr Gene Cooper Consultant

• 40 years pharmaceutical experience

• 10 FDA approved products

• Expert in skin delivery

• Inventor of Permetrex™

Technology and innovation

Dr Joel Gelfand Medical Director of Clinical Studies

Professor James Leyden Scientific Adviser

Professor Diane Thiboutot Scientific Adviser

Steve Newhard Manufacturing/ Quality

• Professor of Dermatology at the University of Pennsylvania

• Expert in skin disease and clinical trial management

• Professor of Dermatology at the University of Pennsylvania

• World leading acne and skin specialist

• Professor of Dermatology at Pennsylvania State University

• Researcher in acne and rosacea

• ▪ Pre-clinical and clinical trials services provider

• 35 years manufacturing and development experience

• Former senior executive with Medicis

• Project leader for formulation

Clinical Studies

Key Opinion Leader

Key Opinion Leader

Formulation/manufacturing

Botanix Pharmaceuticals Ltd.

29

+

==> picture [79 x 27] intentionally omitted <==

Disclaimer

This presentation prepared by Botanix Pharmaceuticals Limited (" Company ") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forwardlooking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Botanix Pharmaceuticals Ltd.

30

+

==> picture [79 x 27] intentionally omitted <==

Disclaimer (cont.)

Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies Ordinance (Cap. 32) of Hong Kong (the "Companies Ordinance"), nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). No action has been taken in Hong Kong to authorise or register this document or to permit the distribution of this document or any documents issued in connection with it. Accordingly, offers of shares by the Company have not been and will not be offered or sold in Hong Kong other than to "professional investors" (as defined in the SFO).

No advertisement, invitation or document relating to shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors (as defined in the SFO and any rules made under that ordinance). No person allotted shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

Botanix Pharmaceuticals Ltd.

31